Eyegate Pharmaceuticals Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 10
Employees
  • Stock Symbol
  • EYEG
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $6.23
  • (As of Friday Closing)

Eyegate Pharmaceuticals General Information

Description

Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary drug delivery system, the EyeGate II Delivery System. It mainly develops EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and ciliary body.

Contact Information

Website
www.eyegatepharma.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 271 Waverley Oaks Road
  • Suite 108
  • Waltham, MA 02452
  • United States
+1 (781) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyegate Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.23 $6.35 $3.20 - $8.18 $43.9M 7.04M 795K -$2.01

Eyegate Pharmaceuticals Financials Summary

In Thousands,
USD 		TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 13,829 34,109 10,312 9,184
Revenue 0 2,686 1,653 408
EBITDA (8,116) (6,895) (10,806) (14,540)
Net Income (8,378) (7,097) (10,811) (13,218)
Total Assets 9,245 10,113 14,281 14,305
Total Debt 340 84 5 16
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eyegate Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eyegate Pharmaceuticals‘s full profile, request access.

Request a free trial

Eyegate Pharmaceuticals Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Eyegate Pharmaceuticals‘s full profile, request access.

Request a free trial

Eyegate Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eyegate Pharmaceuticals Inc is a US-based clinical-stage specialty pharmaceutical company. It focuses on developing and
Drug Discovery
Waltham, MA
10 As of 2019
000.00
000000000 000.00

00000000

henderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
0000 000000000
Boston, MA
0 As of 0000
00.000
000000000 00.000

000000 0

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
000000000000000
Palo Alto, CA
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyegate Pharmaceuticals Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Advanced Proteome Therapeutics Corporate Backed or Acquired Boston, MA 0 00.000 000000000 00.000
000000 00000000 Formerly VC-backed Palo Alto, CA 00 00000 00000000 00000
0000000 Venture Capital-Backed Cambridge, United Kingdom 00 00.000 0000000000 0 00.000
0000000 Formerly VC-backed Jena, Germany 00 00000 000000 - 000 00000
00000 Venture Capital-Backed Cambridge, United Kingdom 000 00000 000000&0 00000
You’re viewing 5 of 15 competitors. Get the full list »

Eyegate Pharmaceuticals Executive Team (7)

Name Title Board Seat Contact Info
Stephen From Chief Executive Officer & Board Member
Sarah Romano Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Michael Manzo Vice President
You’re viewing 3 of 7 executive team members. Get the full list »

Eyegate Pharmaceuticals Board Members (12)

Name Representing Role Since
Bernard Malfroy-Camine Ph.D Self Board Member 000 0000
Illya Maher Eyegate Pharmaceuticals Board Member 000 0000
Morton Goldberg MD Eyegate Pharmaceuticals Board Member 000 0000
Paul Chaney Self Chairman & Board Member 000 0000
Praveen Tyle Ph.D Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Eyegate Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyegate Pharmaceuticals Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 000000 21-Dec-2020 000000000000000000 000.00 Drug Discovery 0000000 0000
Jade Therapeutics 07-Mar-2016 Merger/Acquisition 00.000 Pharmaceuticals 0000000 0000
To view Eyegate Pharmaceuticals’s complete acquisitions history, request access »

Eyegate Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000 Drug Discovery Vienna, Austria 0000
To view Eyegate Pharmaceuticals’s complete subsidiaries history, request access »